The M7e Series features five modules, and are the smallest UHF RFID modules on the market, enabling customers to use the chip in extremely small applications such as handheld RFID scanners, wearable RFID devices, surgical hand scanners, mobile RFID printers and smart vending machines. JADAK will work with healthcare OEMs, retailers, and CPG customers to integrate the module into unique applications worldwide.
In addition to the small size, the modules boast ultra-low power consumption, a necessary requirement for mobile RFID printers, handheld or battery-operated devices used in the retail and inventory tracking spaces. And, each module is capable of varying read rates to accommodate a wide variety of application needs.
One of the most unique features of the M7e Series, as well as all other ThingMagic modules from JADAK is obtaining certification for select countries in advance. JADAK has extensive expertise in regulatory certification and works to obtain these certifications prior to launch, easing the burden on OEMs to obtain their own regulatory certification.
Additional benefits to customers include accuracy, speed, and the ability to track consumer behaviors over time, allowing for inventory changes to better match customer expectations. And the entire M7e Series is also supported by ThingMagic Mercury API, a standardized API used across all ThingMagic products.
JADAK, a business unit of Novanta, is in machine vision, RFID, barcode, printing, and color and light measurement products and services for original equipment manufacturers. The business designs and manufactures automated identification and data collection solutions that help customers solve unique inspection, tracking, scanning and documenting challenges.
JADAK is based in Syracuse, New York, with sales and technical locations across the globe.
Novanta is a trusted technology partner to OEMs in the medical and advanced industrial technology markets, with deep proprietary expertise in photonics, vision, and precision motion technologies.
FDA Grants Breakthrough Device Designation to Tempus' HLA-LOH Companion Diagnostic Test
Nephron Pharmaceutical names new chief procurement officer
Belluscura secures 6,500 DISCOV-R orders, demonstrates strong market demand
Anteris Technologies' DurAVR THV proves successful in second valve-in-valve procedure
Rokit Healthcare receives certification under CEMDR for 'Dr Invivo AI Regen Platform'
AngioDynamics Completes Enrollment for PRESERVE Clinical Study
Paindrainer AB's innovative pain management app secures FDA Class 1 approval
Anteris Technologies Launches ADR program for US investors
Pharming initiates Phase III trial in Japan for leniolisib in APDS treatment
Pharming enrols first patient in Phase III leniolisib clinical trial in Japan
Complement Therapeutics names new chief medical officer
Belluscura expands respiratory offerings with McKesson distribution agreement